Supriya Lifescience Sign Pact with Kalinga Institute to Develop GelHeal

India Pharma Outlook Team | Tuesday, 07 November 2023

 India Pharma Outlook Team

Supriya Lifescience, one of India's leading specialty API manufacturing companies, signs an agreement with Kalinga Institute of Industrial Technology to further develop GelHeal, a protein-based cross-linked hydrogel. The gel-based cream is mapped and designed with the In-Situ scaffold in mind, providing mechanical support to deep wounds and scar-free skin regeneration.

Gel-based ointment can prove effective in the relief and healing of not only third degree wounds, lacerations, bite/ball wounds, but also diabetic foot ulcers, pressure ulcers, venous leg ulcers and surgical wounds. This radical change in dermatology and skin grafting would now also serve scarred skin and would not require repeated hospitalizations with topical skin regeneration gel, proving to be a cost-effective and less time-consuming medical solution for many, as per pharmabiz. With such functions, GelHeal also produces mechanisms to prevent infection, prevent desiccation in humid environments, mechanical support for tension-free wound closure, and support structures to support skin regeneration, resulting in scar-free skin. Dr. Satish Wagh, Supriya Lifescience Ltd. founder and president, says: "Since we have already determined positive changes by recently signing an agreement in collaboration with the Kalinga Institute of Industrial Technology to develop Quickblue, an oral cancer detection kit, we look forward to helping more innovative products like GelHeal, the simplest and cheapest wound gel." Dr. Satish Wagh further said, "Supriya Lifescience has established itself as a CDMO player for decades. Supriya Lifescience is taking a step forward in diversifying our business by leveraging our world-class CDMO capabilities and offering specialized products for healthcare. We believe that more and more such products will make Supriya Lifescience Ltd- i.e. an integrated healthcare provider.

© 2024 India Pharma Outlook. All Rights Reserved.